



domised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. *J Neurol Neurosurg Psychiatry* 2016; 87(10):1127–1132.

11. Guglielmo R, Martinotti G, Di Giannantonio M, Janiri L. A possible new option for migraine management: agomelatine. *Clin Neuropharmacol* 2013; 36(2): 65–67.

12. Hamel E. Serotonin and migraine: biology and clinical implications. *Cephalalgia* 2007; 27(11): 1293–1300.

13. Harnod T, Lin CL, Kao CH. Risk and Predisposing Factors for Suicide Attempts in Patients with Migraine and Status Migrainosus: A Nationwide Population-Based Study. *J Clin Med* 2018; 7(9): 269.

14. Harnod T, Lin CL, Kao CH. Survival outcome and mortality rate in patients with migraine: a population-based cohort study. *J Headache Pain* 2018; 19(1): 57.

15. Chai NC, Peterlin BL, Calhoun AH. Migraine and estrogen. *Curr Opin Neurol* 2014; 27(3): 315–324.

16. Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J. A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache. *PLoS One* 2015; 10(7): e0130733.

17. Jackson JL, Mancuso JM, Nickoloff S, Bernstein R, Kay C. Tricyclic and Tetracyclic Antidepressants for the Prevention of Frequent Episodic or Chronic Tension-Type Headache in Adults: A Systematic Review and Meta-Analysis. *J Gen Intern Med* 2017; 32(12): 1351–1358.

18. Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, Berbano E, O'Malley PG. Tricyclic antidepressants and headaches: systematic review and meta-analysis. *BMJ* 2010; 341: c5222. doi:10.1136/bmj.c5222

19. Karlı N, Baykan B, Ertaş M, et al. Impact of sex hormonal changes on tension-type headache and migraine: a cross-sectional population-based survey in 2,600 women. *J Headache Pain* 2012; 13(7): 557–565.

20. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. *Annu Rev Public Health* 2013; 34:119–138.

21. Kožený J, Höschl C, Tišanská L. Comorbidity of Migraine and Depression – a Meta-analysis. *Cesk Slov Neurol N* 2013; 76/109(6): 712–716.

22. Liu F, Ma T, Che X, Wang Q, Yu S. The Efficacy of Venlafaxine, Flunarizine, and Valproic Acid in the Prophylaxis of Vestibular Migraine. *Front Neurol* 2017; 8: 524.

23. Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: A systematic review. *Medicine (Baltimore)* 2019; 98(3): e14099.

24. Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R, Silbersweig D. Migraine and its psychiatric comorbidities. *J Neurol Neurosurg Psychiatry* 2016; 87: 741–749.

25. Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. *Cochrane Database Syst Rev*. 2005; (3): CD002919.

26. Nović A, Kölves K, O'Dwyer S, De Leo D. Migraine and Suicidal Behaviors: A Systematic Literature Review. *Clin J Pain* 2016; 32(4): 351–364.

27. Orlova Y, Rizzoli P, Loder E. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. *JAMA Neurol* 2018; 75(5): 566–572.

28. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. *Headache* 2005; 45(2): 144–152.

29. Peres MFP, Mercante JPP, Tobo PR, Kamei H, Bigal ME. Anxiety and depression symptoms and migraine: a symptom-based approach research. *J Headache Pain* 2017; 18(1): 37.

30. Plasencia-García BO, Romero-Guillena SL, Quirós-López A, Ruiz-Doblado S. Agomelatine and migraine management: a successfully treated case series. *Ther Adv Psychopharmacol* 2015; 5(4): 243–245.

31. Sacco S, Merki-Feld GS, Aegidius KL, et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). *J Headache Pain* 2018; 19(1): 76.

32. Taylor AP, Adelman JU, Freeman MC. Efficacy of duloxetine as a migraine preventive medication: possible predictors of response in a retrospective chart review. *Headache* 2007; 47(8): 1200–1203.

33. Tomkins GE, Jackson JL, O'Malley PG, Balden E, Santoro JE. Treatment of chronic headache with antidepressants: a meta-analysis. *Am J Med* 2001; 111(1): 54–63.

34. Xu XM, Liu Y, Dong MX, Zou DZ, Wei YD. Tricyclic antidepressants for preventing migraine in adults. *Medicine (Baltimore)* 2017; 96(22):e6989.

35. Yang Y, Zhao H, Heath AC, Madden PA, Martin NG, Nyholt Dr. Shared Genetic Factors Underlie Migraine and Depression. *Twin Res Hum Genet* 2016; 19(4): 341–350.

36. Yang Y, Zhao H, Heath AC, Madden PA, Martin NG, Nyholt Dr. Familial Aggregation of Migraine and Depression: Insights From a Large Australian Twin Sample. *Twin Res Hum Genet* 2016; 19(4): 312–321.

37. Young WB, Bradley KC, Anjum MW, Gebeline-Myers C. Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study. *Headache* 2013; 53(9): 1430–1437.